Federal Research Institute of Pediatric Hematology, Oncology and Immunology

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia

Completed

Conditions: Ataxia Telangiectasia
Dysmetria

First Posted Date: 2022-07-22

Last Posted Date: 2022-07-22

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 5

Registration Number: NCT05471310

Locations: 🇷🇺
Clinical Rehabilitation Research Center "Russkoe pole", Chéjov, Russian Federation

Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents

Phase 3

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Ondansetron
Drug: Dexamethasone
Drug: Aprepitant
Drug: Olanzapine

First Posted Date: 2022-04-26

Last Posted Date: 2022-07-28

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 210

Registration Number: NCT05346731

Locations: 🇷🇺
Zhukov Nikolay, Moscow, Russian Federation

Covid-19 Associated Coagulopathy Predicted by Thrombodynamic Markers (CoViTro-I)

Conditions: Coronavirus Disease 2019

Interventions: Diagnostic Test: Thrombodynamics test

First Posted Date: 2022-04-15

Last Posted Date: 2022-04-15

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 2200

Registration Number: NCT05330832

Locations: 🇷🇺
Dmitry Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

Phase 1

Conditions: Acute Myeloid Leukemia
High Risk Acute Myeloid Leukemia
High Risk Acute Lymphoblastic Leukemia
Acute Biphenotypic Leukemia in Relapse
Non-hodgkin Lymphoma
Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia, in Relapse

Interventions: Biological: boost anti-viral immunity after T-cell depleted HSCT

First Posted Date: 2021-10-04

Last Posted Date: 2021-10-04

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 20

Registration Number: NCT05066958

Locations: 🇷🇺
Federal Research Center for pediatric hematology, oncology and immunology, Moscow, Russian Federation

Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)

Phase 3

Recruiting

Conditions: Acute Lymphoblastic Leukemia, Pediatric
ALL, Infants

Interventions: Combination Product: the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.

First Posted Date: 2021-08-31

Last Posted Date: 2024-06-28

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 80

Registration Number: NCT05029531

Locations: 🇷🇺
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, Samory-Mashela,1, Russian Federation

Total Lymphoid Irradiation Pre-HSCT in Severe Congenital Neutropenia

Phase 2

Not yet recruiting

Conditions: Severe Congenital Neutropenia
GATA2 Deficiency

Interventions: Other: conditioning with TLI

First Posted Date: 2021-04-14

Last Posted Date: 2021-04-14

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 10

Registration Number: NCT04844177

Locations: 🇷🇺
HSCT department, Moscow, Russian Federation

MRI T2* Mapping of Myocardium, Liver, Pancreas and Pituitary Gland

Not Applicable

Conditions: Iron Overload

First Posted Date: 2021-04-08

Last Posted Date: 2021-04-08

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 152

Registration Number: NCT04835285

Locations: 🇷🇺
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, Samory-Mashela,1, Russian Federation

DWI in the Diagnosis of Histological Types of Nephroblastoma in Children

Not Applicable

Conditions: Nephroblastoma (Wilms Tumour)

First Posted Date: 2021-03-24

Last Posted Date: 2021-03-24

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 230

Registration Number: NCT04814758

Locations: 🇷🇺
Dmitry Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Evaluation of Brain Changes in ALL Patients on Therapy

Not Applicable

Recruiting

Conditions: Acute Leukemia

First Posted Date: 2021-02-23

Last Posted Date: 2023-10-30

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 110

Registration Number: NCT04767152

Locations: 🇷🇺
Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology, Moscow, Russian Federation

Quantitative MRI of Bone Marrow in Patients With Acute Lymphoblastic Leukemia

Not Applicable

Recruiting

Conditions: Acute Leukemia

First Posted Date: 2021-02-23

Last Posted Date: 2023-03-08

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 150

Registration Number: NCT04767165

Locations: 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy